Author: admin

  • Drive To Include Pregnant And Breastfeeding Women And Children In Clinical Trials

    Drive To Include Pregnant And Breastfeeding Women And Children In Clinical Trials

    The first woman with malaria in her first trimester of pregnancy was enrolled in a clinical trial to compare three different malaria treatment regimens in Mali on 6 October 2025.

    The first pregnant woman with malaria was enrolled in a clinical…

    Continue Reading

  • Maurice Rutherford obituary | Poetry

    Maurice Rutherford obituary | Poetry

    The work of the poet Maurice Rutherford, who has died aged 103, ranges from love poems and elegies for his late wife to friendly, witty, but sometimes politically trenchant responses to poems by Philip Larkin, and demonstrates that a poet can be…

    Continue Reading

  • First treatment for serious chronic lung disease

    EMA has recommended granting a marketing authorisation in the European Union (EU) for Brinsupri (brensocatib) 25 mg tablets, for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older who have had two or more exacerbations (flare-ups) in the prior 12 months.

    NCFB is a chronic, progressive lung disease resulting in damaged airways and severe pulmonary dysfunction, often leading to chronic cough and airflow obstruction due to abnormal mucus production. It is driven by repeated infections and inflammation, and can be triggered by several causes, including respiratory infections, autoimmune diseases (when the body’s own defence system attacks normal tissue) and immunodeficiency disorders (when body defences are reduced from birth). The estimated number of patients with NCFB in the EU is between 400,000 and three million.

    Patients typically experience between one and four exacerbations per year. Exacerbations are associated with a progressive decline in lung function, decreased quality of life and increased mortality. There are currently no authorised medicines for NCFB; patients rely on airway clearance and receive antibiotics and anti-inflammatory medicines.

    The active substance of Brinsupri is brensocatib, a substance that inhibits dipeptidyl peptidase 1 (DPP1), an enzyme involved in the activation of neutrophils (a type of white blood cells). Recurrent activation of neutrophils in patients with NCFB leads to the excessive release of the proteins neutrophil serine proteases (NSPs), causing airway wall damage, excessive mucus, sustained inflammation and impaired functioning of the immune system. By inhibiting DPP1, brensocatib prevents the activation of NSPs, thereby reducing their harmful activity in the lungs.

    Brinsupri was supported through EMA’s PRIority MEdicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients’ unmet medical needs. EMA’s human medicines committee, the CHMP, reviewed the application for marketing authorisation under an accelerated timetable because Brinsupri is considered to be of major public health interest.

    The recommendation is based on the results of a randomised, double-blind, placebo-controlled clinical trial in 1,767 patients. Patients receiving Brinsupri 25 mg tablets had a 19.4% reduction in the annual rate of pulmonary exacerbations and a 14-week delay in the median time to the first pulmonary exacerbation. The proportion of patients remaining exacerbation-free at week 52 was also significantly higher in those treated with Brinsupri.

    The most common side effects reported with Brinsupri were headache, inflammation of the gums (gingival and periodontal diseases), and problems with the skin, including hyperkeratosis (thick skin), dermatitis (swelling and irritation of the skin), rashes and dry skin.

    The opinion adopted by the CHMP is an intermediary step on Brinsupri’s path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once a marketing authorisation has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role or use of this medicine in the context of the national health system of that country.


    Notes:

    • The total randomised population (1,767) includes both the Brinsupri 10 mg and 25 mg treatment groups.
    • The applicant for Brinsupri is Insmed Netherlands B.V.
    • Brinsupri was granted eligibility to PRIME on 27 February 2020 for the treatment of non-cystic fibrosis bronchiectasis in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

    Continue Reading

  • Weight-loss drug stocks are tumbling after Trump promised their costs ‘will be much lower’

    Weight-loss drug stocks are tumbling after Trump promised their costs ‘will be much lower’

    By Jules Rimmer

    Novo Nordisk, Eli Lilly shares drop

    The price of weight-loss drugs like Ozempic and Wegovy are in the crosshairs of the Trump administration.

    Makers of weight-loss drugs such as Novo Nordisk were under pressure on Friday after President Donald Trump warned he would be pushing down the cost of Ozempic.

    During a press conference in the Oval Office Thursday, President Trump made unplanned remarks about what he refers to as “fat-loss drugs.” A reporter asked him if those drugs could end up costing Americans $150 out of pocket – from a current price of over $1,000 at times – and he agreed and later added they could be “much lower.

    The American depositary receipts of Ozempic’s producer, Novo Nordisk (NVO), promptly shed 5% in short order while the shares of their main competitor in the weight-loss drug market, Eli Lilly (LLY) also tumbled almost 5% in sympathy. Eli Lilly manufacturers similar products, Wegovy and Zepbound.

    Despite soaring sales of these flagship drugs, pharmaceutical stocks have been under pressure this year as the Trump administration has sought to lower the costs of medical treatment in the U.S., while European names have also suffered from the threat of enhanced tariffs on exports to the U.S. This year the Stoxx Europe Pharmaceuticals and Biotechnology index XX:T4570P has fallen 2% compared with the 13% return delivered by the euro Stoxx 50 XX:SX5E benchmark index.

    Despite a 9% rally in the past month, for example, Eli Lilly is still only up 6% for the year, underperforming the S&P 500 SPX by 6 percentage points. Novo Nordisk (DK:NOVO.B), which as recently as this summer was the largest company in Europe by market capitalization, has seen its shares plummet 45% so far in 2025.

    Trump’s off-the-cuff comments were immediately followed up by the head of Medicare and Medicaid, Mehmet Oz, who was quick to jump in and stress, “we haven’t negotiated those yet”. The price of a month’s supply of Ozempic is approximately $1,000, therefore if Trump follows through on his threat then that represents a 15% hit to Novo Nordisk margins.

    Trump made another comment on Ozempic a few weeks ago: “Sometimes it works on people, the ones I’ve seen it hasn’t worked so well. They say to me ‘I’ve lost some weight’, I say ‘you don’t look it to me’,” he said in the Oval Office with Robert F. Kennedy Jr., the secretary of the U.S. Department of Health and Human Services.

    Before it veered off into unscheduled comments, the intention of the press conference was to announce a White House deal with Germany’s pharmaceutical company Merck KGaA (XE:MRK) to reduce the price of fertility treatment in return for a reprieve on tariffs. Other companies such as AstraZeneca (U.K.:AZN) (AZN) and Pfizer (PFE) have negotiated similar deals with the U.S. government.

    Read: Trump rolls out his latest deal with a drugmaker. This one stems from his campaign promise to cover all IVF costs.

    -Jules Rimmer

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

    (END) Dow Jones Newswires

    10-17-25 0605ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • At Just $1,099, This Jackery Power Station Has Never Been Cheaper

    At Just $1,099, This Jackery Power Station Has Never Been Cheaper

    No power? No problem. Whether you live in a part of the world where power outages are a regular occurrence, or you just like to be prepared, a portable power station is certainly a worthwhile investment. They can keep the lights on for hours or…

    Continue Reading

  • Press briefing by UN Women on the situation of women and girls in Gaza – ReliefWeb

    1. Press briefing by UN Women on the situation of women and girls in Gaza  ReliefWeb
    2. Over 1M women, girls in Gaza still need food aid despite ceasefire: UN  TRT World
    3. Feature: Gaza’s mothers, doctors keep hope alive amid conflict, ruin  Xinhua

    Continue Reading

  • 151-million-year-old fly changes what we know about insect evolution |

    151-million-year-old fly changes what we know about insect evolution |

    A remarkable fossil discovery in China is rewriting our understanding of insect evolution. Scientists have identified a 151-million-year-old fly preserved in amber with features not seen in any modern species. The fossil, found in Liaoning…

    Continue Reading

  • The reason art heists exploded in the 1970s

    The reason art heists exploded in the 1970s

    Like the guard injured during the Worcester Art Museum robbery, security employees rarely carried arms – and, as portrayed mockingly in The Mastermind, they could often be dozy “retirees” or “acid heads”, as Reichardt says, with limited…

    Continue Reading

  • ‘Finances are getting tighter’: US car repossessions surge as more Americans default on auto loans | US economy

    ‘Finances are getting tighter’: US car repossessions surge as more Americans default on auto loans | US economy

    Alarm bells are ringing on Wall Street. The recent collapses of Tricolor, a used car seller and sub-prime auto lender, and First Brands, an auto parts supplier, have put the finance industry on edge, almost two decades after problems in the sub-prime mortgage lending market set the stage for the global financial crisis.

    “When you see one cockroach, there are probably more,” Jamie Dimon, the JPMorgan Chase CEO, ominously cautioned analysts this week, after the US’s largest bank disclosed a $170m charge tied to Tricolor’s bankruptcy. “Everyone should be forewarned on this one.”

    As the car lending market shows signs of strain, business around repossessions is booming. “Right now, we’re overwhelmed with work,” George Badeen, who runs Midwest Recovery and Adjustment in Detroit, Michigan, said.

    The so-called repo man, tasked with recovering vehicles from drivers who default on loan agreements, was eulogized in music by Bruce Springsteen and in the 1984 Alex Cox film Repo Man.

    Repossessions – especially in the sub-prime auto market – are on the rise, according to Badeen, who is also president of the Allied Finance Adjusters trade body. “We’ve seen some sub-primes making changes, which probably indicates they’re having issues,” he said. “They’re not financing cars like they were. Two years ago they were financing anybody.”

    While few are bracing for a crisis on the scale of the crash that pushed the world economy to the brink in 2008 – sub-prime auto lending is a fraction of the $1.7tn overall car lending business – the collapses of Tricolor and First Brands have drawn the car sector into the spotlight, amid fears they highlight credit stress in lower-income households, as well as problems in credit markets tied to auto debt.

    First Brands received approval for $500m rescue financing from a bankruptcy court, although Scott Greenberg, an attorney for First Brand’s lenders, told the court of concerns that they could be “lending good money after bad”.

    The wider fear – and the one causing consternation among investors – is what the troubles inside this one market might indicate about broader pressures rippling throughout the wider economy. “Distress in auto lending broadly is often seen as a bellwether to changing circumstances in the US economy, because Americans particularly in the lower-income brackets tend to put their highest priority in auto payments,” said Brett House, an economics professor at Columbia Business School.

    “Having a car is essential to being able to work,” he added. “So when we see stress in the auto financing market, we typically receive that as an indication that household finances are getting tighter.”

    An estimated 100 million Americans hold auto loans, with 85% of new car purchases and 55% of used car purchases financed. It is the third-largest consumer credit market in the US, behind mortgages and student loans.

    Problems in the auto loan industry have been manifesting for several years, as car prices rose sharply during the Covid-19 pandemic while inflation soared and interest rate increases followed. Paying off a new car required 42 weeks of income in 2023, according to Cox Automotive, up from about 33 before the pandemic.

    High prices meant bigger loans. The average monthly repayment now stands at more than $750.

    Car repossessions surged to their highest level since 2009 last year, according to Cox, with 1.73m vehicles seized, up 16% from the year prior and 43% from 2022.

    Car owners were found to be missing payments at the highest rate in more than 30 years in January, when a Fitch Ratings index monitoring the share of sub-prime auto borrowers at least 60 days past due on their loans hit 6.5%.

    “The consumer has been distressed for a little while,” Bill Nash, CEO of CarMax, the biggest seller of used cars in the US, told analysts last month after its lower sales and profits unnerved shareholders. “I think there’s some angst.”

    Auto loans are short-term investments, and Kevin Armstrong, author of Repo Blood: A Century of Auto Repossession History, believes they are often extended to consumers who may not be credit-worthy. For this reason, he said, auto loan delinquencies are often seen as clues – “one of the canaries in the coalmine” – to the health of the broader economy.

    Loan operators are now “giving out massive amounts of loan modification to try to move back delinquencies” to stave off repossession orders, Armstrong said. But they may only be buying time. “There’s a massive amount of recidivism when it comes to loan delinquencies,” he added.

    Armstrong traces the rise in repossessions to the pandemic, when stimulus checks and extra unemployment aid allowed consumers to pay up for pricier cars. “When Covid hit, prices went through the roof,” he said. “I watched people paying outrageous amounts for cars that just weren’t going to hold their value, and the dealers laughing all the way to the bank. They got hosed.”

    Now, coupled with higher mortgage or rental payments, high grocery bills and higher auto loan payments, he added: “Consumers got stuck with loan payments they can’t afford.”

    Under most loan agreements, the lender or leaseholder can repossess the car even if borrowers are only a few weeks behind in payments, in part because a borrower could try to hide the car if they know the lender is looking to repossess it – and potentially sell it at auction.

    The job of repossessing a car is becoming harder, according to Badeen, with greater consumer rights awareness and a higher likelihood of confrontation. “We’ve had so much violence in recent years that we’ve had to train our people in what people like to call situational awareness and de-escalation,” he said. His company typically now sends tow trucks out with two people, one to pick up the car and another to keep watch.

    The clouds gathering over the auto lending market could grow darker. Should Congress fail to agree on a continuation of Covid-era healthcare subsidies, the political issue at the center of the current federal government shutdown, that could put more pressure on the finances of auto borrowers.

    “That whole mess comes out of Covid. It has an impact on individual people that many people don’t understand,” said Badeen. “Everything intertwines in some way, shape or form.”

    If a large sub-prime lender stumbles as a result of this pressure – Santander Consumer is the nation’s biggest, and was last year fined $550m to resolve claims it violated consumer protection laws by placing borrowers with sub-prime credit into auto loans it knew carried an unacceptably high probability of default – there could be wider turbulence.

    Unlike First Brands, Tricolor sought bankruptcy protection last month under the shadow of fraud allegations that have prompted two federal investigations. Charles Gibbs, the attorney representing Tricolor’s court-appointed trustee, told a Texas court this month that initial reports “indicate potentially systemic levels of fraud”.

    “Tricolor’s failure is not necessarily indicative of what is immediately ahead for the sector as a whole, because of the special circumstances, but I would still see it as an economic warning indicator,” said House.

    Armstrong, too, was reluctant to call the failure of the companies, and the rise in repossessions, a trend. “But it’s on the verge,” he added.

    Continue Reading

  • Don’t Remember Someone’s Number? Here’s How to Use T9 Dialing on iPhone Instead

    Don’t Remember Someone’s Number? Here’s How to Use T9 Dialing on iPhone Instead

    I don’t know my wife’s phone number. If I needed to call her and I didn’t have my iPhone, I wouldn’t be able to reach her. And according to a poll by WhistleOut, I’m not alone. About 17% of respondents said they don’t know their partner’s phone…

    Continue Reading